The True Meaning of OCD Explained by Clinical Researchers

Share this post:

LinkedIn
Facebook
X
Reddit
WhatsApp
Print

OCD means obsessive compulsive disorder. In clinical use, the diagnosis refers to a mental disorder marked by obsessions, compulsions, or both. Obsessions are recurrent intrusive unwanted thoughts, urges, or mental images. Compulsions are repetitive behaviors or mental acts that you feel driven to perform in response to an obsession or according to rigid rules. The term does not refer to neatness, strong preferences, or a liking for order.

That pop culture misuse creates real confusion. When people use OCD as shorthand for being tidy, picky, or perfectionistic, they strip out the clinical features that define the disorder. OCD is tied to distress, repetition, loss of control and impaired functioning. Symptoms can consume large parts of your day and can interfere with work, school, sleep, relationships and basic routine tasks.

The formal diagnosis also has a neurological side. Current clinical guidance points to differences in brain circuits involved in emotional response, behavior control and threat processing. That does not reduce OCD to one brain scan finding, but it does place the disorder within brain based psychiatric medicine rather than everyday personality language.

Defining the obsessive component accurately

The obsessive part of OCD refers to repeated intrusive mental events that enter your mind against your wishes and create distress. These can take the form of thoughts, urges, doubts, images, impulses, or fears. They are commonly experienced as unwanted and hard to dismiss. Typical themes include contamination, fear of harm, fear of making a mistake, unwanted sexual thoughts, blasphemous or morally disturbing content, fear of losing control and a need for things to feel exact or complete.

Obsessions are often misunderstood as ordinary worry. The clinical difference is in the way they recur, how intrusive they feel and how strongly they pull you toward a ritual or avoidance pattern. A passing concern about health, safety or morality does not by itself meet the definition. In OCD, the thought keeps returning, feels difficult to dismiss and creates a sense of threat that pushes you toward repetitive responses.

Many people with OCD know that the thought content does not fully match reality, yet the emotional force still feels intense. You may know on one level that the door is locked, your hands are clean, or your memory is likely correct, but the obsession still presses for more certainty. That mismatch between intellectual awareness and felt urgency is a common feature in OCD. Insight can vary from person to person, and some people have better insight than others.

Another point tied to the obsessive component is that the content often targets what you care about most. If safety is central to you, the obsession may involve harm. If morality is central, the obsession may involve guilt, blasphemy, cheating, or taboo ideas. If your focus is cleanliness or disease, contamination fears may dominate. The content can look different from one person to another, but the clinical pattern stays tied to intrusive recurrence and distress.

Defining the compulsive component accurately

The compulsive part of OCD refers to repetitive acts done to reduce distress, neutralize a thought, or prevent a feared event. These acts can be visible or hidden. Visible compulsions include washing, checking, arranging, touching, repeating actions and seeking reassurance from others. Hidden compulsions include counting, praying, reviewing memories, mentally repeating phrases, mentally canceling a thought and scanning your own feelings for certainty.

A compulsion is not just a strong habit. A habit may be routine and automatic, but a compulsion is tied to pressure, fear and temporary relief. The person usually feels driven to do it. The act may briefly lower anxiety, disgust, guilt or tension, then the distress returns and the cycle starts again. That short relief is one reason the disorder can become self reinforcing over time.

Compulsions can also follow rigid personal rules that feel hard to break. You may need to repeat a task until it feels complete, check an item a certain number of times, arrange objects until they feel exact, or silently repeat a phrase until the tension drops. The feared outcome may be concrete, such as illness or fire, or vague, such as a sense that something bad will happen or that a thought says something terrible about you.

The hidden side of compulsions is one reason OCD can go unnoticed. A person can look calm while carrying out long internal rituals. Family, coworkers and clinicians may first notice lateness, indecision, avoidance, repeated questions, sleep loss or fatigue rather than the ritual itself. Accurate clinical assessment depends on asking about mental acts and reassurance seeking, not just visible checking or washing.

The clinical criteria for a formal diagnosis

A formal diagnosis of OCD generally requires obsessions, compulsions, or both. These symptoms must be time consuming, usually taking more than one hour per day, or they must cause clinically significant distress or impairment in social, occupational, academic, or other important areas of functioning. This threshold helps separate a psychiatric disorder from isolated quirks, preferences, or occasional intrusive thoughts.

Clinicians also look at function. If symptoms delay you for hours, interfere with work, damage relationships, keep you from leaving the house, block normal routines, or absorb large parts of your mental energy, that supports the diagnosis. The issue is not the topic of the fear alone. The issue is the full pattern of intrusion, ritual, distress and impairment.

The diagnosis also requires that the symptoms are not better explained by the effects of a substance, another medical condition, or another mental disorder. This step matters because repetitive thoughts and behaviors can also appear in eating disorders, body dysmorphic disorder, illness anxiety, psychotic disorders, tic disorders and other conditions. Careful diagnostic work sorts out the source and function of the symptoms before a formal label is applied.

Clinical evaluation often includes the level of insight. Some people recognize that their OCD beliefs are probably untrue or may be untrue. Others hold them with much stronger conviction. Clinicians may also note if the person has a current or past tic disorder, since that can shape the clinical picture and sometimes treatment planning.

Age of onset can also support the picture, though it is not itself a diagnostic rule. Symptoms commonly begin between late childhood and young adulthood. The form can shift over time. A person may move from contamination fears to checking, from visible rituals to mental rituals, or from one obsession theme to another. The diagnosis still rests on the same core criteria of obsessions, compulsions, time burden, distress and impairment.

Accurate definitions carry practical weight in clinical care. If OCD is mistaken for perfectionism, overthinking, or a simple personality trait, diagnosis can be delayed and treatment can miss the repetitive fear ritual loop that keeps symptoms active. A correct definition gives you a clearer path to assessment, treatment planning and measurement of symptom severity over time.

Conclusion

Treating serious psychiatric conditions starts with accurate definitions, and we at Rose Hill Life Sciences apply rigorous scientific standards across our research programs. We are a psychedelic research organization specializing in the production and research of Psilocybe cubensis, operating at the intersection of science and therapeutic integration, and are based in Massachusetts.



Disclaimer: The information in this article is for educational and informational purposes only and does not constitute medical advice.

You May Also Like

Adam Goodman

Advisor

Adam is a seasoned entrepreneur with a wealth of experience in spearheading real estate development and management endeavors. His focus primarily lies in land development, where he orchestrates the intricate tapestry of planning and zoning entitlements, while meticulously overseeing all facets of engineering and architectural design, leasing, construction, and financing.

With a national reach spanning 23 states and encompassing over 250 properties, totaling more than 6 million square feet, Adam’s proficiency in navigating the complexities of the industry is evident.

Beyond real estate, Adam’s endeavors extend into the realm of alternative investments, boasting successful ventures in healthcare, professional sports franchises, financial services, diverse agricultural platforms, and the stewardship of local restaurants.

 

Rotem Petranker, PhD, Psychology

Psychedelic Researcher

Rotem Petranker is a psychedelics researcher with a particular emphasis on microdosing, therapy, research methods and research ethics. He earned his BSc from the University of Toronto, his Master’s degree from York University, and his PhD from McMaster University.

As part of my research, I have gained extensive expertise in navigating the regulatory landscapes of Health Canada and the FDA and a strong background in designing rigorous clinical trial research methodologies. 

I founded the Canadian Centre for Psychedelic Science in 2018, established the Psychedelic Science Research Program at the University of Toronto in 2019, and, more recently, ran the largest clinical trial to date on the effectiveness of microdosing psilocybin for Major Depressive Disorders. I have published many papers on microdosing, including some of the largest samples in the literature and some that have set standards for performing psychedelic research.

Kevin Bourke

Chief Commercial Officer

Kevin Bourke is a dynamic executive and strategic planner whose career spans over two decades of crafting and elevating world-class Jamaican brands and transformational experiences on the global stage. With a keen understanding of culture, identity, and international markets, he has played a pivotal role in shaping some of Jamaica’s most iconic names — including Appleton Estate Rum, Chris Blackwell’s Rum, and Usain Bolt’s Tracks & Records — bringing them from local roots to international acclaim. His leadership and vision have also been instrumental in major cultural movements such as Fiction and the internationally recognized TmrwTday Wellness Festival.

An innovator at heart, Mr. Bourke seamlessly blends brand strategy with deep cultural resonance. His ability to connect with diverse audiences has established these brands not only as commercial successes but as symbolic ambassadors of Jamaican excellence, fortifying the island’s influence in beverage, music, lifestyle, and experiential sectors.

In recent years, Kevin has steered his strategic acumen toward the cutting-edge psilocybin and wellness industry, becoming a co-founder and Chief Marketing and Branding Officer of Rose Hill, Jamaica’s leading cultivator, exporter, and innovator of psilocybin products and experiences. Through ventures like ONE Retreats, he has helped craft safe, guided psychedelic-assisted healing programs that attract participants from around the world seeking deep personal transformation, including military veterans and international wellness seekers.

Kevin’s impact extends beyond business into industry shaping and policy, as he sits on the Jamaica Psilocybin Mushroom Industry Technical Committee (under the Bureau of Standards) — a pivotal body that is formalizing guidelines and regulatory standards for the emerging legal psilocybin sector in Jamaica. His presence on this committee underscores his leadership role in ensuring the industry’s integrity, safety, and sustainable growth.

Highly regarded for his extensive network throughout Jamaica and internationally, Kevin remains passionately committed to advancing ethical, high-integrity product development and customer-centric experiences at every level. His dedication is driven not only by professional achievement but by a deep vision for human well-being, cultural celebration, and the global evolution of plant-based healing.

Jama Pitman

Regulatory Strategy

Jama Pitman is a seasoned biopharmaceutical executive with extensive expertise in global drug development and commercialization. With over two decades of experience, she has contributed to the development of groundbreaking therapies across oncology, rare diseases, and antivirals. As a strategic leader, she has successfully transitioned companies from private to public markets, navigated complex M&A transactions, and driven innovative drug approvals.

Jama has held executive roles in leading organizations, including Deciphera Pharmaceuticals, where she played a pivotal role in scaling operations from a small, privately held biotech company to a global, multi-product company acquired for $2.4 billion. She brings exceptional skills in regulatory affairs, portfolio management, quality assurance, and clinical operations, longside a proven track record of fostering inclusivity and mentorship within her teams.

Currently, as the founder of JP BioPharma Consulting, Jama advises biopharma and tech companies on accelerating drug development and achieving corporate goals. Her collaborative and forward-thinking approach aligns seamlessly with Rose Hill’s mission to advance transformative therapies in mental health and beyond.

Education: B.Sc. in Microbiology, University of New Hampshire.

Notable Achievements: Contributed to the development of multiple FDA-approved therapies, including QINLOCK® for gastrointestinal stromal tumors.

Domenic Suppa

Chief Operating Officer

Domenic is co-founder and the Operations Chief of Rose Hill Health Holdings.

He has been working as a Cannabis technology and operations veteran with more than 11 years’ experience as a senior executive in an operationally complex, and highly regulated industry.

His introduction and entrance into the Cannabis sector started in 2010 with a seed investment into a Denver-based vertically integrated cannabis company called, Evolab. He served as C.O.O. for 5 years from 2013-2018, through the eventual acquisition by Harvest Health and Recreation (HARV: CSE).

Domenic moved on to be acting COO of the manufacturing division for Supreme Cannabis (CSE: FIRE) and supported the acquisition of BLISSCO (CSE: BLISS, a BC-based cannabis manufacturer). Domenic has worked with high-profile national cannabis brands including KKE, and Monogram, and retail brands in MA Native Sun, Terps, and Tilt. Domenic is a proven leader and team builder; his previous experiences have all been with early-stage and growth equity enterprises.

He has refined and evolved his leadership roles, including his team-building skills. He is a value creator. Domenic is a firm believer in training and continuous development. He excels in employing practices, tools, and methodologies designed to achieve maximum process efficiency while minimizing waste and delays.

 

Burton J. Tabaac

Clinical Development

Dr. Burton J. Tabaac, MD, FAHA, brings a wealth of expertise in neurology and stroke rehabilitation to Rose Hill. As an Associate Professor and Section Chief of Neurology at The University of Nevada’s Reno School of Medicine, and Medical Director of Stroke at Carson Tahoe Health, Dr. Tabaac has been at the forefront of innovative neurological treatments.

A graduate of the prestigious cerebrovascular neurology fellowship program at The Johns Hopkins University Hospital, Dr. Tabaac’s accolades include being a three-time recipient of The Arnold P. Gold Foundation’s Humanism and Excellence in Teaching Award and induction into the Alpha Omega Alpha Honor Medical Society.

He recently published an eight-part paper in the American Journal of Therapeutics reviewing psychedelics as therapeutics for primary care clinicians. Dr. Tabaac’s groundbreaking research focuses on the application of psychedelics in brain injury and stroke rehabilitation.

Dr. Tabaac was recently appointed by the Governor of Nevada to serve as a member of the state’s Psychedelic Medicines Working Group, which provides expertise and testimony relating to the therapeutic use of entheogens.

As the host of The Zero Hour Podcast, he engages with leading experts in psychedelic research. His commitment to advancing the field was further highlighted in his 2022 TEDx talk at UCLA, “Mental Health Meets Psychedelics.”

“Joining Rose Hill’s advisory team presents an exciting opportunity to further explore the potential of psilocybin in neurological recovery,” said Dr. Tabaac.

“The company’s commitment to ethical cultivation and research aligns perfectly with my vision for advancing patient care through innovative therapies. I’m eager to bring my expertise to Rose Hill and contribute to the evolving landscape of psychedelic medicine.”

Charles Lazarus

Chief Executive Office

Mr. Lazarus boasts over 16 years of extensive expertise in psilocybin and cannabis, focusing on genetic development, cultivation, extraction, and operations logistics. Notably, he recently achieved a milestone by cultivating and delivering the largest legal shipment of premium psilocybin globally.

As an accomplished owner/operator, Mr. Lazarus has successfully managed multiple farming and harvesting businesses, earning commendations for his unwavering commitment to quality and impressive output volumes. Since 2015, he has been actively involved in producing proprietary psilocybin genetics and cultivation solutions tailored for the Jamaican market and large research and development clients.

His contributions span various aspects, including genetic development, cultivation, extraction, harvest, and logistics. Additionally, Mr. Lazarus owned and operated Island Fresh Ltd., a venture that played a pivotal role in exporting fresh fruit, ground provisions, and promoting brand Jamaica to the English market. Under his leadership, Island Fresh Ltd. achieved the highest volume from Jamaica for three consecutive years.

Mr. Lazarus’s extensive experience also includes serving as the Harvest Manager for cannabis grow operations in California from 2013 to 2017, further solidifying his comprehensive knowledge in the cannabis industry.